Efficacy, safety and tolerability of fesoterodine in asian patients with overactive bladder

LUTS: Lower Urinary Tract Symptoms

Volumn 3, Issue 1, 2011, Pages 43-50

  Yamaguchi, Osamu ^a   Nishizawa, Osamu ^b   Takeda, Masayuki ^c   Yoshida, Masaki ^d   Choo, Myung Soo ^e   Gu Lee, Jeong ^f   Tong Long Lin, Alex ^g   Lin, Ho Hsiung ^h   Andrew Yip, Wai Chun ⁱ   Isowa, Hitoshi ^j   Hiro, Shintaro ^j  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d KUMAMOTO ROSAI HOSPITAL   (Japan)

^e University of Ulsan College of Medicine   (South Korea)

^f Korea University College of Medicine   (South Korea)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁱ KWONG WAH HOSPITAL   (Hong Kong)

^j PFIZER INC   (United States)

more..

Author keywords

Fesoterodine; Overactive bladder; Randomized controlled trial

Indexed keywords

FESOTERODINE; PLACEBO;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; ASIAN; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FEMALE; HEART RATE; HONG KONG; HUMAN; JAPAN; KOREA; MAJOR CLINICAL STUDY; MALE; MICTURITION; MORNING DOSAGE; OVERACTIVE BLADDER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TAIWAN; URGE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

EID: 79954615494     PISSN: 17575664     EISSN: 17575672     Source Type: Journal    
DOI: 10.1111/j.1757-5672.2011.00091.x     Document Type: Article

References (18)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
2. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36.
3. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-15.
4. Homma Y, Yamaguchi O, Hayashi K. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 2005; 96: 1314-18.
5. Lee YS, Lee KS, Jung JH et al. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol 2009. DOI: 10.1007/s00345-009-0490-1.
6. Yu HJ, Liu CY, Lee KL, Lee WC, Chen TH. Overactive bladder syndrome among community-dwelling adults in Taiwan: prevalence, correlates, perception, and treatment seeking. Urol Int 2006; 77: 327-33.
7. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62.
8. Andersson KE, Chapple CR, Cardozo L et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19: 380-94.
9. Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 169-72.
10. Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12.
11. Nitti VW, Dmochowski R, Sand PK et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178: 2488-94.
12. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079-86.
13. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-9.
14. Reese PR, Pleil AM, Okano GJ, Kelleher CJ. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003; 12: 427-42.
15. Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res 2002; 11: 563-74.
16. Cardozo L, Khullar V, Wang JT, Guan Z, Sand PK. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int 2010; 106: 816-21.
17. van Leeuwen JH, Castro R, Busse M, Bemelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006; 50: 440-53.
18. Yalcin I, Bump RC. The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. Am J Obstet Gynecol 2004; 191: 194-7.